TC Biopharm (Holdings) Plc (TCBP)
NASDAQ: TCBP · Real-Time Price · USD
0.630
+0.035 (5.83%)
Nov 20, 2024, 4:00 PM EST - Market closed
TC Biopharm (Holdings) Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | - | - | 3.84 | 1.98 | 1.98 | 3.43 |
| Revenue Growth (YoY) | - | - | 94.30% | 0% | -42.26% | - |
| Gross Profit | - | - | 3.84 | 1.98 | 1.98 | 3.43 |
| Selling, General & Admin | 6.78 | 6.87 | 8.74 | 3.11 | 2.21 | 3.01 |
| Research & Development | 6.73 | 7.37 | 7.19 | 6.16 | 6.68 | 8.61 |
| Other Operating Expenses | -0.02 | - | - | - | -0.02 | -1.56 |
| Operating Expenses | 13.5 | 14.24 | 15.93 | 9.27 | 8.87 | 10.07 |
| Operating Income | -13.5 | -14.24 | -12.08 | -7.29 | -6.89 | -6.64 |
| Interest Expense | -0.08 | -0.08 | -6.75 | -3.44 | -0.29 | -0.28 |
| Interest & Investment Income | - | - | - | 0 | 0 | 0.02 |
| Currency Exchange Gain (Loss) | -0.08 | -0.08 | -0.12 | -0.08 | - | - |
| Other Non Operating Income (Expenses) | 4.92 | 8.05 | 16.06 | -4.18 | - | - |
| EBT Excluding Unusual Items | -8.75 | -6.35 | -2.89 | -14.99 | -7.18 | -6.89 |
| Other Unusual Items | -0.65 | -0.65 | -0.14 | 0.01 | 0.55 | - |
| Pretax Income | -9.39 | -7 | -3.03 | -14.98 | -6.63 | -6.89 |
| Income Tax Expense | -0.8 | -1.09 | -1.72 | -1.41 | -1.17 | -0.83 |
| Net Income | -8.59 | -5.91 | -1.31 | -13.58 | -5.46 | -6.07 |
| Net Income to Common | -8.59 | -5.91 | -1.31 | -13.58 | -5.46 | -6.07 |
| Shares Outstanding (Basic) | 0 | 0 | - | - | - | - |
| Shares Outstanding (Diluted) | 0 | 0 | - | - | - | - |
| EPS (Basic) | -130.21 | -191.21 | - | - | - | - |
| EPS (Diluted) | -130.21 | -191.21 | - | - | - | - |
| Free Cash Flow | -10.03 | -10.66 | -15.53 | -5.6 | -3.47 | -8.76 |
| Free Cash Flow Per Share | -152.00 | -344.92 | - | - | - | - |
| Gross Margin | - | - | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | - | - | -314.32% | -368.28% | -348.05% | -193.78% |
| Profit Margin | - | - | -34.17% | -686.12% | -275.84% | -177.07% |
| Free Cash Flow Margin | - | - | -404.03% | -283.07% | -175.21% | -255.52% |
| EBITDA | -12.92 | -13.61 | -11.32 | -6.48 | -6.01 | -5.92 |
| EBITDA Margin | - | - | -294.48% | - | - | -172.71% |
| D&A For EBITDA | 0.58 | 0.63 | 0.76 | 0.81 | 0.88 | 0.72 |
| EBIT | -13.5 | -14.24 | -12.08 | -7.29 | -6.89 | -6.64 |
| EBIT Margin | - | - | - | - | - | -193.78% |
Source: S&P Capital IQ. Standard template.
Financial Sources.